CMO exercises stock options, immediately sells all shares for nearly $2.7M gain; net neutral position in unprofitable biotech.
Azoulay Salomon, Chief Medical Officer of MBX Biosciences, exercised stock options and liquidated the entire resulting position on the same day for a notable profit spread: acquiring shares at roughly $10–$16 per share and selling them immediately at approximately $38 per share. This is a classic option-exercise-and-sell transaction—a common way insiders monetize compensation. The pattern itself is not unusual, but the execution matters: Salomon is disposing of shares in a company losing money and trading well below its 52-week high, while also in the third year of Form 4 filings at this company with a track record of selling (two prior sales in the 36-month window). The net zero holdings position after this filing means Salomon holds no residual equity stake, despite having just exercised options—suggesting this was a pure liquidity event rather than a vote of confidence in the company's direction. For a biotech firm burning cash, seeing an officer take profits and walk away entirely is worth noting.